SABS SAB Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%
Returns
ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $1.32M | $2.24M | $23.90M | $60.88M |
| R&D expense | $34.35M | $30.25M | $16.52M | $36.44M | $57.18M |
| SG&A expense | $14.60M | $13.98M | $23.80M | $16.38M | $17.09M |
| Operating income | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M |
| Interest expense | $240,664 | $318,401 | $315,284 | $301,584 | $294,459 |
| Pretax income | $13.27M | — | -$42.19M | -$18.72M | -$17.14M |
| Income tax | $0 | $0 | $0 | $25,629 | $0 |
| Net income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M |
| EBITDA | -$45.96M | -$38.20M | -$34.42M | -$25.75M | -$11.90M |
| EPS (basic) | 0.22 | -3.68 | -7.64 | -4.31 | -0.63 |
| EPS (diluted) | -0.79 | -3.68 | -7.64 | -4.31 | -0.63 |
| Weighted avg. shares (diluted) | 61.34M | 9.26M | 5.52M | 4.35M | 27.34M |
| Balance sheet | |||||
| Cash & equivalents | $10.50M | $8.90M | $56.57M | $15.05M | $33.21M |
| Short-term investments | $86.09M | $11.86M | $0 | — | — |
| Receivables | — | — | $0 | $5.56M | $8.01M |
| Current assets | $101.05M | $23.79M | $58.91M | $22.10M | $50.19M |
| PP&E, net | $13.31M | $15.37M | $19.74M | $23.25M | $24.31M |
| Total assets | $172.81M | $44.20M | $83.94M | $50.90M | $81.14M |
| Current liabilities | $10.68M | $7.98M | $10.81M | $14.99M | $26.46M |
| Total liabilities | $21.32M | $18.23M | $26.64M | $19.85M | $42.59M |
| Shareholders' equity | $151.50M | $25.97M | $57.30M | $31.06M | $38.55M |
| Shares outstanding | 47.61M | 9.29M | 9.23M | 5.04M | 43.49M |
| Cash flow statement | |||||
| Operating cash flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M |
| Capital expenditure | $933,156 | $337,262 | $197,154 | $2.17M | $10.94M |
| Free cash flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | -$8.96M |
| Investing cash flow | -$121.71M | -$11.96M | -$152,704 | -$2.09M | -$10.94M |
| Financing cash flow | $168.30M | -$1.17M | $66.77M | $1.05M | $35.89M |
| Depreciation & amortization | $2.99M | $4.71M | $3.65M | $3.17M | $1.49M |
| Stock-based compensation | $5.21M | $2.94M | $2.42M | $2.67M | $2.31M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.